These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 27602665)

  • 1. Adalimumab in Patients with Active Noninfectious Uveitis.
    Jaffe GJ; Dick AD; Brézin AP; Nguyen QD; Thorne JE; Kestelyn P; Barisani-Asenbauer T; Franco P; Heiligenhaus A; Scales D; Chu DS; Camez A; Kwatra NV; Song AP; Kron M; Tari S; Suhler EB
    N Engl J Med; 2016 Sep; 375(10):932-43. PubMed ID: 27602665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.
    Nguyen QD; Merrill PT; Jaffe GJ; Dick AD; Kurup SK; Sheppard J; Schlaen A; Pavesio C; Cimino L; Van Calster J; Camez AA; Kwatra NV; Song AP; Kron M; Tari S; Brézin AP
    Lancet; 2016 Sep; 388(10050):1183-92. PubMed ID: 27542302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III.
    Suhler EB; Adán A; Brézin AP; Fortin E; Goto H; Jaffe GJ; Kaburaki T; Kramer M; Lim LL; Muccioli C; Nguyen QD; Van Calster J; Cimino L; Kron M; Song AP; Liu J; Pathai S; Camez A; Schlaen A; van Velthoven MEJ; Vitale AT; Zierhut M; Tari S; Dick AD
    Ophthalmology; 2018 Jul; 125(7):1075-1087. PubMed ID: 29429764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.
    Sheppard J; Joshi A; Betts KA; Hudgens S; Tari S; Chen N; Skup M; Dick AD
    JAMA Ophthalmol; 2017 Jun; 135(6):511-518. PubMed ID: 28426849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
    Suhler EB; Jaffe GJ; Fortin E; Lim LL; Merrill PT; Dick AD; Brezin AP; Nguyen QD; Thorne JE; Van Calster J; Cimino L; Adan A; Goto H; Kaburaki T; Kramer M; Vitale AT; Kron M; Song AP; Liu J; Pathai S; Douglas KM; Schlaen A; Muccioli C; Van Velthoven MEJ; Zierhut M; Rosenbaum JT
    Ophthalmology; 2021 Jun; 128(6):899-909. PubMed ID: 33157077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial.
    Srivastava SK; Watkins TR; Nguyen QD; Sharma S; Scales DK; Dacey MS; Shah RE; Chu DS; Grewal DS; Faia LJ; Suhler EB; Genovese MC; Guo Y; Barchuk WT; Besuyen R; Dick AD; Rosenbaum JT
    JAMA Ophthalmol; 2024 Sep; 142(9):789-797. PubMed ID: 39023880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis.
    Ramanan AV; Dick AD; Jones AP; McKay A; Williamson PR; Compeyrot-Lacassagne S; Hardwick B; Hickey H; Hughes D; Woo P; Benton D; Edelsten C; Beresford MW;
    N Engl J Med; 2017 Apr; 376(17):1637-1646. PubMed ID: 28445659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.
    Letko E; Yeh S; Foster CS; Pleyer U; Brigell M; Grosskreutz CL;
    Ophthalmology; 2015 May; 122(5):939-48. PubMed ID: 25638011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab: A Review in Non-Infectious Non-Anterior Uveitis.
    Hoy SM
    BioDrugs; 2017 Apr; 31(2):135-142. PubMed ID: 28229433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab for the treatment of refractory active and inactive non-infectious uveitis.
    Lee JT; Yates WB; Rogers S; Wakefield D; McCluskey P; Lim LL
    Br J Ophthalmol; 2018 Dec; 102(12):1672-1678. PubMed ID: 29459430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study.
    Hamam RN; Barikian AW; Antonios RS; Abdulaal MR; Alameddine RM; El Mollayess G; Mansour AM
    Ocul Immunol Inflamm; 2016 Jun; 24(3):319-26. PubMed ID: 25549063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis.
    Park SE; Jun JW; Lee DH; Lee SC; Kim M
    Yonsei Med J; 2021 Feb; 62(2):177-181. PubMed ID: 33527798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials.
    Suhler EB; Thorne JE; Mittal M; Betts KA; Tari S; Camez A; Bao Y; Joshi A
    Ophthalmology; 2017 Dec; 124(12):1799-1807. PubMed ID: 28689898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Switching from Adalimumab Originator to SB5, Adalimumab Biosimilar for Noninfectious Uveitis.
    Song SH; Woo SJ
    Ocul Immunol Inflamm; 2024 Oct; 32(8):1755-1759. PubMed ID: 38194436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA).
    Nguyen QD; Merrill PT; Clark WL; Banker AS; Fardeau C; Franco P; LeHoang P; Ohno S; Rathinam SR; Thurau S; Abraham A; Wilson L; Yang Y; Shams N;
    Ophthalmology; 2016 Nov; 123(11):2413-2423. PubMed ID: 27692526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
    Al-Janabi A; El Nokrashy A; Sharief L; Nagendran V; Lightman S; Tomkins-Netzer O
    Ophthalmology; 2020 Mar; 127(3):410-416. PubMed ID: 31607412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab in Elderly Patients with Non-Infectious Uveitis. Safety and Efficacy.
    Moll-Udina A; Miguel Escuder L; Hernanz I; Llorenç V; Fonollosa A; Cordero Coma M; Sainz de la Maza M; Espinosa G; González Guijarro JJ; Lopez Lopez F; Alba-Linero C; Hernández M; Martínez Costa L; Celdrán Vivancos D; Giralt L; Artaraz J; Soler Bartrina P; Jódar Márquez M; García de Vicuña R; Esquinas C; Adán A
    Ocul Immunol Inflamm; 2021 Nov; 29(7-8):1591-1598. PubMed ID: 32657649
    [No Abstract]   [Full Text] [Related]  

  • 18. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials.
    Dick AD; Tugal-Tutkun I; Foster S; Zierhut M; Melissa Liew SH; Bezlyak V; Androudi S
    Ophthalmology; 2013 Apr; 120(4):777-87. PubMed ID: 23290985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab for Treatment of Noninfectious Uveitis: Immunogenicity and Clinical Relevance of Measuring Serum Drug Levels and Antidrug Antibodies.
    Cordero-Coma M; Calleja-Antolín S; Garzo-García I; Nuñez-Garnés AM; Álvarez-Castro C; Franco-Benito M; Ruiz de Morales JG
    Ophthalmology; 2016 Dec; 123(12):2618-2625. PubMed ID: 27692527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.
    Nussenblatt RB; Peterson JS; Foster CS; Rao NA; See RF; Letko E; Buggage RR
    Ophthalmology; 2005 May; 112(5):764-70. PubMed ID: 15878055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.